STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Taysha (TSHA) Insider Files Form 144 for 10,770 Shares

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Taysha Gene Therapies (TSHA) filing a Form 144 notifies the planned sale of 10,770 shares of common stock through Maxim Group on Nasdaq with an aggregate market value of $30,479.10. The shares were acquired and vested as RSU awards on 09/22/2025 and settled in stock as consideration for the reporting person’s service. The filing shows 272,794,885 shares outstanding and reports no other sales in the past three months. The filer certifies no undisclosed material adverse information.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine insider sale disclosure of vested RSUs; transaction size is immaterial to total shares outstanding.

The Form 144 documents a planned sale of 10,770 shares via a broker on Nasdaq, stemming from RSUs that vested and were settled in stock on the same date. With 272.8 million shares outstanding, the position represents roughly 0.0039% of the outstanding stock, indicating limited direct market impact. The filing includes the required certification regarding material nonpublic information.

TL;DR: Standard disclosure consistent with Rule 144 procedures following RSU vesting and settlement.

The notice provides the broker name, exact share count, acquisition and planned sale date, and nature of acquisition (RSU award). It confirms no sales in the prior three months and includes the statutory signature caution, fulfilling disclosure obligations under the rule. No governance or compliance issues are evident from the content provided.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the TSHA Form 144 report?

The filing reports a proposed sale of 10,770 common shares acquired via RSU vesting and settled in stock on 09/22/2025.

Who is the broker handling the proposed TSHA sale?

The broker named in the filing is Maxim Group LLC, with the sale to occur on Nasdaq.

What is the aggregate market value of the shares to be sold for TSHA?

The aggregate market value reported is $30,479.10 for the 10,770 shares.

How do these shares compare to TSHA's outstanding shares?

The filing lists 272,794,885 shares outstanding; the 10,770-share sale is approximately 0.0039% of that total.

Were there any other sales by the reporting person in the past three months?

The filing states Nothing to Report for securities sold during the past three months.
Taysha Gene Therapies, Inc.

NASDAQ:TSHA

TSHA Rankings

TSHA Latest News

TSHA Latest SEC Filings

TSHA Stock Data

1.33B
243.67M
11.15%
94.76%
14.95%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
DALLAS